RxDoctor Payments DataLook up a doctor →

Alan Brook, MD

Pulmonary Disease · Saint Peters, MONPI 1316938863

Payments from drug & device makers

$15,735in general payments, 2019–2025

Across 896 payments — averaging $17.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$3K
  • AstraZeneca$3K
  • Boehringer Ingelheim$847
  • Grifols USA, LLC$799
  • Regeneron Healthcare Solutions, Inc.$552
  • Sanofi$544
  • plus $7K from 42 others

What the payments were for

  • Food & beverage$15,62499%
  • Education$1111%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$15,735 in reported general payments places this provider in the 75th percentile of 295 pulmonary disease providers in Missouri.

See all pulmonary disease providers in Missouri

Medicare billing

Part B allowed, 2024
$237,343
Medicare patients
774
Services billed
3,131

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter354$322,687
OpsumitMacitentan12$154,085
Breo ElliptaFluticasone/Vilanterol177$77,429
Breztri AerosphereBudesonide/Glycopyr/Formoterol100$66,630
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr114$65,730
Dupixent SyringeDupilumab12$43,933
Stiolto RespimatTiotropium Br/Olodaterol Hcl60$37,010
Spiriva RespimatTiotropium Bromide38$32,764
XareltoRivaroxaban33$21,673
EliquisApixaban16$16,249
Spiriva HandihalerTiotropium Bromide25$15,559
Incruse ElliptaUmeclidinium Bromide21$13,924
Arnuity ElliptaFluticasone Furoate44$13,446
ArexvyRsvpref3 Antigen/As01e/Pf50$13,065
Pirfenidone12$11,832

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta, Arnuity Ellipta$3,051$506,280760 claims
Actelion Pharmaceuticals US, Inc.Opsumit$525$154,08512 claims
AstraZenecaBreztri Aerosphere, Symbicort, Bevespi Aerosphere$3,050$88,945153 claims
Boehringer IngelheimStiolto Respimat, Spiriva Respimat$847$69,77498 claims
Johnson & JohnsonXarelto$32$21,67333 claims
PfizerEliquis$203$16,24916 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 295 pulmonary disease providers in Missouri.

Other pulmonary disease in Saint Peters

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →